Cytomegalovirus (CMV), a common virus in the Herpesviridae family, infects approximately half of all adults in the United States, most of whom experience mild or no symptoms. While the virus usually ...

11. Martín-Gandul C, et al. Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients. Journal of Infection. 2014;69 (5):500-506.

Without screening all newborns for CMV, those who appear normal at birth will not be fully evaluated, considered for treatment or monitored for effects that develop later, such as hearing loss.

Takeda. Health Canada approves Takeda’s LIVTENCITY™ (maribavir) the first and only treatment for adults with post-transplant cytomegalovirus (CMV) infection.

Maribavir is FDA approved for treatment of post-transplant CMV infection in patients ≥ 12 years old and weighing ≥ 35 kg, which is refractory to treatment (with or without genotypic resistance ...

An estimated 40% to 80% of people worldwide are chronically infected with cytomegalovirus, a virus in the herpes family that doesn't usually cause symptoms in healthy people but is a common cause ...

About 20% to 60% of people who have a solid organ transplant develop a symptomatic CMV infection. It’s one of the most common complications for solid organ transplant recipients.

Congenital CMV and hearing loss About 1 out of every 200 babies in the US is born with congenital CMV, and the virus is the leading cause of birth defects in children.